We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-14.64%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.19B
AUM Growth
-$126M
Cap. Flow
+$122M
Cap. Flow %
10.23%
Top 10 Hldgs %
29.08%
Holding
134
New
12
Increased
77
Reduced
4
Closed
6

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$10.7M
2
WBA
Walgreens Boots Alliance
WBA
+$9.86M
3
ALKS icon
Alkermes
ALKS
+$7.68M
4
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$7.42M
5
RDUS
Radius Health, Inc.
RDUS
+$7.3M

Top Sells

Rank Stock Value
1
IDXX icon
Idexx Laboratories
IDXX
+$9.3M
2
RLYP
RELYPSA INC COM
RLYP
+$7.14M
3
ABBV icon
AbbVie
ABBV
+$5.18M
4
DYAX
DYAX CORPORATION
DYAX
+$4.67M
5
TVTX icon
Travere Therapeutics
TVTX
+$2.33M

Sector Composition

Rank Sector Weight
1 Healthcare 77.87%
2 Financials 3.87%
3 Industrials 0.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AET
1
DELISTED
Aetna Inc
AET
$46.2M 3.87%
411,000
– –
AGN
2
DELISTED
Allergan plc
AGN
$45.8M 3.84%
171,000
+9,000
+6% +$2.58M
ACHC icon
3
Acadia Healthcare
ACHC
$2.52B
$41.3M 3.46%
749,500
+74,500
+11% +$4.25M
HCA icon
4
HCA Healthcare
HCA
$90.6B
$33.6M 2.81%
430,000
– –
BXLT
5
DELISTED
BAXALTA INC COM STK (DE)
BXLT
$32.7M 2.74%
810,000
– –
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
$31.7M 2.66%
227,750
+34,750
+18% +$5.1M
PFE icon
7
Pfizer
PFE
$143B
$30.8M 2.58%
1,094,368
+66,718
+6% +$1.91M
GILD icon
8
Gilead Sciences
GILD
$165B
$30.3M 2.54%
330,300
+5,000
+2% +$451K
AAAP
9
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$29.2M 2.44%
833,000
+33,000
+4% +$989K
RDUS
10
DELISTED
Radius Health, Inc.
RDUS
$25.4M 2.13%
808,500
+211,000
+35% +$7.3M
ISRG icon
11
Intuitive Surgical
ISRG
$127B
$25.2M 2.12%
378,000
+22,500
+6% +$1.39M
CELG
12
DELISTED
Celgene Corp
CELG
$24M 2.01%
239,500
+9,500
+4% +$978K
WCG
13
DELISTED
Wellcare Health Plans, Inc.
WCG
$21.3M 1.79%
230,000
+15,500
+7% +$1.29M
TEVA icon
14
Teva Pharmaceuticals
TEVA
$40.4B
$21.1M 1.77%
395,000
+15,700
+4% +$921K
COLL icon
15
Collegium Pharmaceutical
COLL
$1.18B
$20.8M 1.74%
1,145,000
+139,513
+14% +$2.54M
MDCO
16
DELISTED
Medicines Co
MDCO
$20.1M 1.68%
632,000
+7,000
+1% +$229K
LLY icon
17
Eli Lilly
LLY
$1.08T
$19.9M 1.67%
276,000
+103
+0% +$7.79K
PCRX icon
18
Pacira BioSciences
PCRX
$1.04B
$17.3M 1.45%
326,500
+66,500
+26% +$3.89M
ONCE
19
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$17.1M 1.44%
580,500
+20,500
+4% +$647K
ACRS icon
20
Aclaris Therapeutics
ACRS
$715M
$17M 1.42%
895,500
-654
-0.1% -$12.5K
ELV icon
21
Elevance Health
ELV
$81.5B
$16.8M 1.41%
121,000
+200
+0.2% +$26.7K
CI icon
22
Cigna
CI
$78.4B
$16.7M 1.4%
122,000
– –
TSRO
23
DELISTED
TESARO, Inc.
TSRO
$16.7M 1.4%
379,500
+45,500
+14% +$1.83M
NBIX icon
24
Neurocrine Biosciences
NBIX
$18.2B
$16M 1.34%
404,500
+27,000
+7% +$1.07M
TMO icon
25
Thermo Fisher Scientific
TMO
$214B
$14.2M 1.19%
100,200
+200
+0.2% +$26.8K
1
2 3 4 5

Similar funds

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
ISS
Intesa Sanpaolo SpA. Turin, Italy $1.69B AUM
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return

Rock Springs Capital Management's Q1 2016 Portfolio in Review

As of Q1 2016, Rock Springs Capital Management held 134 positions worth $1.19B, down 9.6% from $1.32B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rock Springs Capital Management deployed $122M of net new capital in Q1 2016, opening 12 new positions and adding to 77 existing holdings. Its largest new stake was Bristol-Myers Squibb: 170,000 shares worth $10.9M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 77% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Travere Therapeutics, an estimated $2.33M trimmed.

  • Rock Springs Capital Management's largest Q1 2016 buy was Bristol-Myers Squibb: 170,000 shares worth $10.9M.
  • Rock Springs Capital Management added most to ANACOR PHARMACEUTICALS INC COM in Q1 2016, an estimated $7.42M increase.
  • Rock Springs Capital Management's biggest Q1 2016 reduction was Travere Therapeutics, cutting an estimated $2.33M.
  • Rock Springs Capital Management fully exited Idexx Laboratories in Q1 2016, selling an estimated $9.3M.
  • Rock Springs Capital Management's ten largest holdings make up 29% of its $1.19B portfolio in Q1 2016.
  • Rock Springs Capital Management opened 12 new positions and closed 6 in Q1 2016.
  • Rock Springs Capital Management's portfolio value fell 9.6% quarter-over-quarter to $1.19B.

Based on Rock Springs Capital Management's 13F filing for Q1 2016, filed 16 May 2016.